Adial PharmaceuticalsADIL
13F holders, Q2 2025 (June 30)16holders +4
5new positions
1sold out
$0.30avg. 13F price*
At the end of Q2 2025, 16 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, up 4 from Q1 2025. 5 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($21K), Manchester Capital Management LLC ($15K) and BlackRock, Inc. ($8K).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A205
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $18K |
| Exits | 1 | $17K |
All 13F filers, Q1 2025 → Q2 2025: 61,837 shares bought and 61,772 shares sold, net +65 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Geode Capital Management, LLC | 0.00% | No change | 68,850 | $21K |
| Manchester Capital Management LLC | 0.00% | No change | 48,097 | $15K |
| BlackRock, Inc. | 0.00% | No change | 27,770 | $8K |
| Jane Street Group, LLC | 0.00% | New | 24,862 | $8K |
| HRT Financial LP | 0.00% | New | 19,090 | $5K |
| Vanguard Group Inc. | 0.00% | No change | 13,159 | $4K |
| UBS Group AG | 0.00% | Reduce -74.0% | 12,395 | $4K |
| Two Sigma Investments, LP | 0.00% | New | 10,802 | $3K |
| Citigroup Inc. | 0.00% | New | 3,974 | $1K |
| Stone House Investment Management, LLC | 0.00% | New | 2,700 | $816 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.6% | 1,419 | $429 |
| SBI Securities Co., Ltd. | 0.00% | Add +42.2% | 1,318 | $398 |
| Wells Fargo & Company | 0.00% | No change | 160 | $48 |
| Bank of America Corp. | 0.00% | Add +32.7% | 73 | $22 |
| Abound Wealth Management | 0.00% | No change | 27 | $9 |
| Morgan Stanley | 0.00% | No change | 9 | $3 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.